Merck & Co plans to file cough drug gefapixant after phase 3 success
pharmaphorum
SEPTEMBER 9, 2020
Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, said: “COUGH-1 and COUGH-2 are the first companion Phase 3 trials in refractory or unexplained chronic cough, underscoring Merck’s commitment to fully researching the potential for gefapixant in this patient population.
Let's personalize your content